Previous Article | Next Article 
Journal of Virology, May 1999, p. 4293-4298, Vol. 73, No. 5
0022-538X/99/$04.00+0
Adeno-Associated Virus (AAV) Type 5 Rep Protein
Cleaves a Unique Terminal Resolution Site Compared with Other
AAV Serotypes
John A.
Chiorini,
Sandra
Afione, and
Robert M.
Kotin*
Molecular Hematology Branch, National Heart,
Lung, and Blood Institute, Bethesda, Maryland 20892
Received 25 November 1998/Accepted 18 February 1999
 |
ABSTRACT |
Adeno-associated virus (AAV) replication depends on two viral
components for replication: the AAV nonstructural proteins (Rep) in
trans, and inverted terminal repeat (ITR) sequences in
cis. AAV type 5 (AAV5) is a distinct virus compared to the
other cloned AAV serotypes. Whereas the Rep proteins and ITRs of other
serotypes are interchangeable and can be used to produce recombinant
viral particles of a different serotype, AAV5 Rep proteins cannot
cross-complement in the packaging of a genome with an AAV2 ITR. In
vitro replication assays indicated that the block occurs at the level
of replication instead of at viral assembly. AAV2 and AAV5 Rep binding
activities demonstrate similar affinities for either an AAV2 or AAV5
ITR; however, comparison of terminal resolution site (TRS) endonuclease activities showed a difference in specificity for the two DNA sequences. AAV2 Rep78 cleaved only a type 2 ITR DNA sequence, and AAV5
Rep78 cleaved only a type 5 probe efficiently. Mapping of the AAV5 ITR
TRS identified a distinct cleavage site (AGTG TGGC) which is absent
from the ITRs of other AAV serotypes. Comparison of the TRSs in the
AAV2 ITR, the AAV5 ITR, and the AAV chromosome 19 integration locus
identified some conserved nucleotides downstream of the cleavage site
but little homology upstream.
 |
INTRODUCTION |
A key step in the infectious cycle
of adeno-associated virus (AAV) is the replication of the viral genome.
Two viral components are required for replication: the AAV
nonstructural proteins (Rep), and the inverted terminal repeat (ITR)
sequences at the end of the viral genome. The Rep open reading frame
(ORF) of AAV encodes four related proteins that are transcribed from
one of two promoters along with a splice variant of each. These four
proteins are referred to by their apparent molecular sizes of 78, 68, 52, 40 kDa. Rep78 and Rep68 are necessary for viral DNA replication
(3, 14, 25, 35), whereas Rep52 and Rep40 function as DNA
helicases (2) and facilitate the accumulation of
single-stranded progeny virus (30).
Two of the Rep proteins (Rep78 and Rep68) bind DNA in a
sequence-specific manner and can nick duplex ITRs in a site- and
strand-specific manner (6, 15, 33). This cleavage reaction
occurs at the terminal resolution site (TRS) within the ITR and permits
the replication of the ends of the linear genome. DNA binding requires a tandem repeat of a GAGY motif which is present in the ITR structures at the ends of the viral genome (4, 6, 26, 28, 32). Furthermore, DNA binding and terminal resolution are central to the
preferential integration of the AAV genome into a region on the q arm
of human chromosome 19 (18, 29, 35, 37).
In addition to the role of the Rep proteins in the life cycle of AAV,
their expression results in a characteristic phenotype. Overexpression
of Rep68 and Rep78 has been shown to either negatively or positively
affect transcription, to inhibit cellular transformation, (11-13,
17, 20, 21), and to inhibit progression through the cell cycle
(10, 39). The importance of the Rep proteins is emphasized
by their high degree of conservation among four of the five sequenced
AAV serotypes (5, 8, 24, 27, 34).
The ITRs can fold into T-shaped hairpin structures and serve as the
origins of viral DNA replication. Two elements within the ITR are
central to its function: a GAGY repeat motif and the TRS (RGTTGG). The
ITRs of AAV serotypes 2, 3, 4, 5, and 6 (AAV2 to -6) exhibit sequence
differences, but the ability to fold into a hairpin conformation and
the existence of a Rep binding motif are conserved. The TRS is
conserved only in AAV2, -3, -4, and -6.
The Rep proteins of AAV2, -3, -4, and -6 are approximately 90%
identical, with most of the changes being conservative amino acid
substitutions. This high degree of conservation of the Rep gene and ITR
among the serotypes results in cross-complementation among the Rep
genes and ITRs of different serotypes (8).
In contrast, the Rep gene and ITR of AAV5 are only 60% similar to
those of the other serotypes and fail to cross-complement with other
serotypes (5); i.e., no AAV2 ITR-containing genomes can be
packaged by using AAV5 Rep. However, viral particles are produced if
the AAV2 Rep ORF is included. From these data, we hypothesize that the
lack of complementation is not at the level of viral assembly
that is,
viral DNA packaging
but is rather at the level of viral DNA
replication. Comparison of the ITR sequence of AAV5 with those of the
other serotypes identified a Rep binding motif; however, only a partial
consensus TRS could be identified in the AAV5 ITR. Thus, AAV5 Rep
proteins may have an endonuclease different from those of the other AAV serotypes.
In this study, we confirmed our hypothesis that the lack of
cross-complementation occurs at the level of DNA replication. AAV5 and
AAV2 Rep proteins were shown to bind the ITRs of the other serotype;
however, efficient TRS endonuclease activity was detected only in their
respective ITRs. Mapping of the AAV5 Rep terminal resolution
endonuclease activity identified a novel recognition sequence that is
present only in the AAV5 ITR.
 |
MATERIALS AND METHODS |
Plasmids and DNA.
All oligonucleotide probes were purified
on denaturing polyacrylamide gels before being annealed and on native
gels after being annealed. Construction of recombinant AAV2
(AAV2RnLacZ) and AAV5 (AAV5RnLacZ) vector plasmids expressing
nucleus-localized
-galactosidase is described elsewhere (5,
7). The P1 element from the AAV integration locus was cloned into
pUC19, producing pMAT50 (37). The Rep ORF of AAV5 was cloned
into the maltose binding protein (MBP) expression plasmid pMAL-c2 by
PCR amplification of AAV5 DNA (nucleotides [nt] 359 to 3600) with
Pfu polymerase (Statagene, La Jolla, Calif.). The PCR
product was digested with XhoI, which cuts at nt 3589. The
3.2-kb fragment was cloned into the XmnI and SalI
sites of pMAL-c2 (New England Biolabs, Beverly, Mass.). The construct
was verified by sequencing. The recombinant AAV5 MBP-Rep78 fusion
protein was also expressed in Escherichia coli and purified
by using an amylose affinity resin (New England Biolabs). The MBP-Rep78
fusion protein had a molecular mass of 115 kDa as determined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. For in vitro
translation of AAV5 Rep78, AAV5 DNA was cut with NruI and a
1.9-kb fragment was isolated and cloned into the SmaI site
of pGem3Zf. AAV2 MBP-Rep78 and in vitro-translated AAV2 Rep78
expression plasmids are described elsewhere (6, 31).
In vitro replication assay.
HeLa S3 cell extracts were
prepared as described elsewhere (36). The replication assays
were performed as described previously (35), with the
following modifications: the total dCTP concentration was 10 µM, and
the reaction mixtures were preincubated for 1.5 h before the
addition of [
-32P]dCTP (5,000 Ci/mmol; Amersham). Each
assay mixture contained 0.1 mg of cellular protein in a final volume of
15 µl; 4 mM ATP; 200 µM (each) CTP, GTP, and UTP; 100 µM (each)
dATP, dGTP, and dTTP; 10 µCi of [
-32P]dCTP; 2 mM
dithiothreitol (DTT); 2 µg of creatine phosphokinase; 300 ng of
plasmid DNA; and, when indicated, 1 µg of recombinant Rep protein.
Reaction mixtures were incubated at 34°C for 16 to 18 h. The
level of stimulation of replication was determined by the amount of
32P in the acid-precipitable material and assayed by
thin-layer chromotography (TLC). Aliquots of each reaction mixture were
assayed by spotting them on silica gel TLC plates (Baker-flex Silica
Gel 1B; J. T. Baker, Phillipsburg, N.J.). The unincorporated
nucleotides were separated from acid-precipitable DNA by development of
the plates with 1 M HCl. The level of 32P was determined
with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). For
samples analyzed by agarose gel electrophoresis, unincorporated
nucleotides were removed from reaction mixtures by the use of a
nucleotide removal kit (Qiagen, Valencia, Calif.), and the DNA was
resolved on 0.6% agarose gels, dried, and autoradiographed.
EMSAs.
Electrophoretic mobility shift assays (EMSAs) were
performed as described previously (6). Briefly, gel-purified
radiolabeled probes (50,000 cpm) were incubated with 100 to 200 ng of
purified AAV2 MBP-Rep78 or AAV5 MBP-Rep78 in a 15-µl reaction mixture
containing shift buffer (40 mM Tris-HCl [pH 8], 50 mM NaCl, 10 mM
MgCl2, 1 mM DTT, 4% glycerol, 0.1 mg of bovine serum
albumin per ml) at 30°C for 15 min. The reaction mixtures were then
cooled to 4°C, and 5 µl of sample loading dye was added to each.
The DNA-protein complexes were then resolved on 4% nondenaturing
polyacrylamide gels, dried, and autoradiographed.
Terminal resolution endonuclease assays.
Site- and
strand-specific endonuclease assays were performed as described
previously (6) with the following modifications. A 2-µl
aliquot of in vitro-translated AAV2 Rep78 or AAV5 Rep78 was added,
along with radioactively 5'-end-labeled probe (50,000 cpm) to a 15-µl
reaction volume containing TRS buffer [25 mM
piperazine-N,N'-bis(2-ethanosulfonic acid)
[PIPES], 4 mM MgCl2, 1 mM DTT, 1 mM ATP, 0.1 mg of bovine serum albumin/ml]. Reaction mixtures were incubated for 1 h at 37°C, and then the reactions were terminated by addition of 5 µl of
formamide gel loading buffer followed by heating to 80°C for 5 min.
The reaction products were resolved on 10% polyacrylamide-urea gels
(Novex). The gels were fixed in 10% methanol and 10% acetic acid
followed by gel drying solution (Novex) prior to being dried and
subjected to autoradiography. The TRS mapping experiments were
performed with the same reaction mixture, but the reactions were
terminated with stop buffer (10 mM Tris-HCl [pH 7.9], 10 mM NaCl,
0.5% sodium dodecyl sulfate, 0.2 mg of yeast tRNA/ml, 20 mM EDTA, 2 mg
of proteinase K/ml). The reaction mixtures were incubated in stop
buffer for 30 min at 37°C, and the nucleic acid was purified by
phenol-chloroform extraction and ethanol precipitation. The DNA was
resuspended in formamide gel loading buffer and resolved on a 6%
polyacrylamide sequencing gel, which was subsequently dried and
subjected to autoradiography. The sizes of the cleavage products were
determined by comparison to the products of a purine-specific sequencing reaction of the labeled probe (Sigma Chemical Co.) (23).
 |
RESULTS |
Cross-complementation refers to the ability of a protein of one
serotype to replicate and package the genome of an alternative serotype. To determine whether cross-complementation is occurring at
the level of DNA synthesis with heterologous Rep proteins, AAV2 or AAV5
ITR-containing genomes were tested in an in vitro replication assay
that included either AAV2 or AAV5 Rep proteins.
The DNA templates (AAV2RnLacZ and AAV5RnLacZ) tested in the replication
assay were the recombinant genomes used in the packaging experiments
and contained the ITR of either AAV2 or AAV5 flanking a
nucleus-localized
-galactosidase gene with a Rous sarcoma virus promoter. These plasmids lack the Rep and Cap ORFs of AAV. Addition of
the AAV2RnLacZ DNA to HeLa cell lysate supplemented with recombinant AAV2 MBP-Rep78 resulted in a 12-fold increase in DNA replication compared to control reactions (lysate minus Rep) (Fig.
1A, bar 1) as measured by radiolabel
incorporation (Fig. 1A, bar 2). A similar increase in DNA replication
was measured when the AAV5RnLacZ DNA was added to HeLa cell lysate
supplemented with AAV5 MBP-Rep78 (Fig. 1A, bar 6). In contrast, little
or no DNA replication was detected if AAV5 Rep was added to AAV2RnLacZ
DNA or AAV2 Rep was added to AAV5RnLacZ DNA (Fig. 1A, bars 3 and 5, respectively).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
In vitro replication. (A) The effect of the MBP-Rep
fusion protein from AAV-2 or AAV-5 on DNA replication was measured by
TLC (see Materials and Methods). One of two templates was tested in the
in vitro replication assay: AAV2RnLacZ or AAV5RnLacZ (bars 1 to 3 and 4 to 6, respectively). Background incorporation was defined as the amount
of incorporation measured in the absence of Rep protein (bars 1 and 4).
(B) Effects of AAV2 and AAV5 MBP-Rep78 with pMAT50 on replication.
Replication reactions were performed as described in Materials and
Methods, and the replication products were resolved by agarose gel
electrophoresis. AAV2 and AAV5 MBP-Rep78 proteins were included in
lanes 2 and 3, respectively; lane 1, extract only, no Rep. The
open-circular (O) and linear (L) forms of pMAT50 are indicated.
|
|
AAV2 Rep protein can also initiate DNA replication from a cellular DNA
fragment isolated from the AAV integration locus (35, 37).
This fragment (P1) contains a Rep binding motif as well as a TRS, both
of which are necessary for P1 to function as an origin of DNA
replication (35). As previously described, the addition of a
P1-containing plasmid to HeLa cell lysate supplemented with AAV2
MBP-Rep78 resulted in a 10-fold increase in DNA replication (Fig. 1B,
lane 2) (35). However, only background levels of radiolabel incorporation were measured if no Rep or AAV5 MBP-Rep78 was added to
the HeLa cell lysate (Fig. 1B, lanes 1 and 3).
The above results support our hypothesis that the lack of
cross-complementation occurs at the level of DNA replication. AAV DNA
replication requires both a Rep binding motif and an adjacent TRS
motif. Comparison of the ITR sequence of AAV5 with those of the AAV2
ITR and the P1 fragment identified repeats of the GAGY Rep binding
motif in all three. However, the AAV5 ITR contained only a weak
consensus TRS compared to the AAV2 ITR and the P1 fragment (Fig.
2).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 2.
Sequence and alignment of ITR and probes. (Top) Sequence
of the P1 element contained within the SmaI subfragment of
AAVS1 (nt 354 to 468) (37). (Middle) Sequence of the AAV2
ITR as previously described (34). (Bottom) Sequence of the
AAV5 ITR as previously described (5). Linear probes used in
the EMSA and TRS assays are indicated by brackets flanking the AAV2 and
AAV5 ITR stem regions. Rep binding motifs are boxed and labeled. TRSs
are boxed and labeled, and the site of cleavage in each is indicated by
a vertical arrow.
|
|
To compare the DNA binding activities of AAV5 MBP-Rep78 and AAV2
MBP-Rep78 with either the AAV2 ITR or AAV5 ITR, we performed EMSAs
using truncated ITR probes (Fig. 3). Both
Rep proteins formed complexes with either probe, producing slightly
different shift patterns with the different Rep proteins. The AAV5
MBP-Rep78 complex migrated slightly faster than the AAV2 Rep complex
with either the type 2 or type 5 ITR probe (Fig. 3). This mobility
difference most likely results from the reduced size and more acidic
charge of AAV5 Rep78 compared to AAV2 Rep78. Addition of a 20-fold
excess of cold competitor DNA inhibited all four shift complexes three- to fourfold, suggesting that AAV2 and AAV5 Rep proteins have similar binding affinities for either probe (Fig. 3, lanes 5, 10, 15, and 20).

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 3.
EMSAs. Gel-purified radiolabeled probes (50,000 cpm
each) were incubated with 100 ng of purified AAV2 MBP-Rep78 or AAV5
MBP-Rep78 as indicated. In the absence of protein, no shift complex was
detected (lanes 1, 6, 11, and 16). The addition of purified AAV2
MBP-Rep78 (lanes 2 and 12) or AAV5 MBP-Rep78 (lanes 7 and 17) resulted
in the formation of a shift complex. Binding competition studies were
done in the presence of a 5-fold (lanes 3, 8, 13, and 18), 10-fold
(lanes 4, 9, 14, and 19), or 20-fold (lanes 5, 10, 15, and 20) molar
excess of unlabeled probe. Quantitation of the shift complex was done
with a scanning densitometer (Molecular Dynamics). Bound, bound probe;
free, free probe.
|
|
Characterization of the TRS endonuclease activities of AAV2 and AAV5
Rep proteins on either the AAV2 or AAV5 ITR showed a difference in
specificity for the two probes. Incubation of in vitro-translated AAV2
Rep78 with the AAV2 ITR probe radiolabeled on the 5' end of the D'A
strand generated a cleavage product of the expected size (Fig.
4, lane 6). In contrast, no cleavage
product was detected with AAV2 Rep78 and the AAV5 ITR (Fig. 4, lane 5). In vitro-translated AAV5 Rep78 demonstrated a similar specificity for
its own ITR compared to the AAV2 ITR. AAV5 Rep78 produced a major
cleavage when AAV5 Rep78 was incubated with the AAV5 ITR probe; in
contrast, a very faint band was detected when AAV5 Rep78 was incubated
with the AAV2 ITR probe (Fig. 4, lanes 3 and 4, respectively). The
inefficient cleavage of the AAV2 ITR by AAV5 Rep78 indicates that in
the absence of its cognate TRS, AAV5 Rep78 may utilize a nonnative TRS.
Thus, AAV2 Rep78 and AAV5 Rep78 have similar DNA binding affinities for
the two probes but lack efficient TRS endonuclease cross-reactivity.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 4.
TRS specificity. In vitro-translated AAV2 Rep78 or AAV5
Rep78 was incubated with radiolabeled probe (50,000 cpm), and the
products were resolved on denaturing gels. The positions of the
full-length substrate and cleavage products are indicated by arrows.
Lanes: 1 and 2, probe alone; 3 and 4, AAV5 Rep78 with the AAV5 and AAV2
ITRs, respectively; 5 and 6, AAV2 Rep78 with the AAV5 and AAV2 ITRs,
respectively. The upper arrow identifies the AAV5 cleavage product
(lane 3), and the lower arrow indicates the AAV2 cleavage product (lane
6).
|
|
Previous research mapped the AAV2 TRS to a unique site (AGTTGG) on the
D'A strand (15, 33). To map the AAV5 TRS, the cleavage reactions were repeated with the AAV5 ITR probe derived from the stem
region of the ITR (Fig. 2). 5'-End-labeled D'A or A'D duplexed oligonucleotide probes were incubated with either AAV2 or AAV5 MBP-Rep
and resolved on a sequencing gel (Fig.
5). The site of cleavage was determined
by comparison with a G+A chemical sequencing reaction and is
diagrammatically indicated in Fig. 2. AAV5 Rep78-directed cleavage was
detected only on the coding strand (D'A) and not on the noncoding
strand (A'D) (Fig. 5, lanes 6 and 3, respectively). As in Fig. 4, some
minor cleavage products were also detected with AAV2 Rep78 on the D'A
probe (Fig. 5, lane 5). As stated above, this may represent an ability
of Rep78 to cleave at a suboptimal site when a preferred site is not
present.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 5.
TRS mapping of the AAV5 ITR.
32P-5'-end-labeled oligonucleotide probes (A'D or D'A) were
annealed with unlabeled complementary oligonucleotides and incubated
with either recombinant MBP-AAV2 Rep78 (lanes 2 and 5) or MBP-AAV5
Rep78 (lanes 3 and 6). The position of the cleavage product is
indicated by an arrow. The sizes of the cleavage products were
determined by comparison to the products of purine-specific sequencing
reactions of the labeled probe (lanes 1 and 4). The sequence of the
labeled oligonucleotide probe is on the left of each panel, with the
Rep binding motif and TRS homolog indicated by brackets.
|
|
The cleavage site is positioned 21 to 25 bases upstream of the GAGY Rep
binding motif, compared to the 16 to 20 bases in the AAV2 ITR. Whereas
the AAV5 DNA upstream of the cleavage site has little homology with the
AAV2 DNA, some homology exists downstream of the TRS. In both AAV2 and
AAV5, the TGGC motif immediately downstream of the cleavage site is
conserved. This sequence is followed by a pyrimidine-rich region which
abuts the Rep binding motif (Fig. 2). The sequence surrounding the TRS
is conserved proximal to the Rep binding sites in P1, AAV2, and AAV5
(TGG); there is a lack of homology upstream. However, the spacing
between the GAGY motif and the TRS is reduced, and the pyrimidine-rich region present in the AAV ITRs is absent.
 |
DISCUSSION |
AAV5 is the only dependent parvovirus that was originally isolated
from a patient sample instead of from laboratory stocks of adenovirus
(1). In this study, the discrete TRS endonuclease activity
of type 5 Rep in comparison to that of type 2 Rep further defines AAV5
as a unique dependovirus. The ITR and Rep protein of AAV5 are distinct
and do not complement those of AAV2. In vitro replication experiments
indicate that the lack of cross-reactivity occurs at the level of DNA
replication. Although further biochemical analysis demonstrated that
AAV2 Rep78 and AAV5 Rep78 will bind to either AAV2 or AAV5 ITR probes
with similar affinities, comparison of their TRS endonuclease
activities showed a difference in specificity for the two DNA
sequences. AAV2 Rep78 would only cleave an AAV2 ITR DNA sequence, and
AAV5 Rep78 had a very strong preference for cleaving the AAV5 ITR DNA sequence.
Despite the differences in TRS specificity, there are conserved
sequence elements within the probes. The sequence immediately downstream of the cleavage site (TGG) is common to all three probes. Further downstream of the cleavage site, both the AAV2 ITR and the AAV5
ITR contain a pyrimidine tract between the TRS site and the Rep binding
motif. In contrast, in P1, the spacing is reduced and the pyrimidine
tract is absent. Because of its absence from the P1 fragment, the
pyrimidine tract may not be important for Rep binding or TRS activity;
instead, this region may promote stability of the ITR hairpin
structure, which cannot form in the P1 fragment.
Rep-mediated cleavage of the P1 fragment is central to the integration
of AAV2 at the AAVS1 cellular locus on chromosome 19 (22).
Initiation of DNA synthesis results from Rep cleavage of these DNA
substrates. The type 5 Rep proteins are unable to initiate DNA
synthesis in vitro from these substrates as a result of their unique
TRS endonuclease activity. By extension of the model for type 2 integration, AAV5 integration may occur at a unique locus compared to
the other serotypes of AAV.
The Rep consensus binding motif consists of at least two repeats of
GAGY (9). These repeats have been identified in a number of
cellular loci (9, 38) and are reported to affect gene transcription (19). Based on analysis of the AAVS1
integration locus, a TRS adjacent to the Rep binding motif is also
required for the site to function in targeted integration
(22). For AAV2, the requirement of a properly positioned TRS
and a Rep binding motif may further reduce the probability of the
sequence's occurrence to that of a unique site in the human genome
(35). This is supported by the preferential integration of
AAV2 at the chromosome 19 locus (16). Whereas AAV5 Rep
recognizes a TRS distinct from that recognized by AAV2 Rep, the
probability of this sequence occurring adjacent to a Rep binding site
will be similar to that for AAV2.
Sequence analysis, capsid interactions, packaging efficiency, and
biochemical activities define AAV5 as being unique among the
dependoviruses. Several of these features will have applications for
the field of gene therapy and the development of recombinant and
chimeric vectors. Comparison of the amino acid sequences and biochemical activities of AAV5 Rep and AAV2 Rep will also be useful for
defining the Rep DNA binding domain, as well as amino acids that are
involved in TRS endonuclease activity.
 |
ACKNOWLEDGMENTS |
We thank Richard H. Smith and Michael Schmidt for review of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: NIH/NHLBI/MHB,
Bldg. 10/7D18, 10 Center Dr. MSC 1654, Bethesda, MD 20892-1654. Phone: (301) 496-1594. Fax: (301) 496-9985. E-mail:
Kotinr{at}fido.nhlbi.nih.gov.
 |
REFERENCES |
| 1.
|
Bantel-Schall, U., and H. zur Hausen.
1984.
Characterization of the DNA of a defective human parvovirus isolated from a genital site.
Virology
134:52-63[Medline].
|
| 2.
|
Chejanovsky, N., and B. J. Carter.
1989.
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication.
Virology
173:120-128[Medline].
|
| 3.
|
Chejanovsky, N., and B. J. Carter.
1989.
Replication of a human parvovirus nonsense mutant in mammalian cells containing an inducible amber suppressor.
Virology
171:239-247[Medline].
|
| 4.
|
Chiorini, J. A.,
S. M. Wiener,
R. A. Owens,
S. R. M. Kyöstiö,
R. M. Kotin, and B. Safer.
1994.
Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats.
J. Virol.
68:7448-7457[Abstract/Free Full Text].
|
| 5.
|
Chiorini, J. A.,
F. Kim,
L. Yang, and R. M. Kotin.
1999.
Cloning and characterization of adeno-associated virus type 5.
J. Virol.
73:1309-1319[Abstract/Free Full Text].
|
| 6.
|
Chiorini, J. A.,
M. D. Weitzman,
R. A. Owens,
E. Urcelay,
B. Safer, and R. M. Kotin.
1994.
Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli.
J. Virol.
68:797-804[Abstract/Free Full Text].
|
| 7.
|
Chiorini, J. A.,
C. M. Wendtner,
E. Urcelay,
B. Safer,
M. Hallek, and R. M. Kotin.
1995.
High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors.
Hum. Gene Ther.
6:1531-1541[Medline].
|
| 8.
|
Chiorini, J. A.,
L. Yang,
Y. Lui,
B. Safer, and R. M. Kotin.
1997.
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles.
J. Virol.
71:6823-6833[Abstract].
|
| 9.
|
Chiorini, J. A.,
L. Yang,
B. Safer, and R. M. Kotin.
1995.
Determination of adeno-associated virus Rep68 and Rep78 binding sites by random sequence oligonucleotide selection.
J. Virol.
69:7334-7338[Abstract].
|
| 10.
|
Hermanns, J.,
A. Schulze,
P. Jansen-Dürr,
J. A. Kleinschmidt,
R. Schmidt, and H. zur Hausen.
1997.
Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins.
J. Virol.
71:6020-6027[Abstract].
|
| 11.
|
Hermonat, P. L.
1989.
The adeno-associated virus Rep78 gene inhibits cellular transformation induced by bovine papillomavirus.
Virology
172:253-261[Medline].
|
| 12.
|
Hermonat, P. L.
1991.
Inhibition of H-ras expression by the adeno-associated virus Rep78 transformation suppressor gene product.
Cancer Res.
51:3373-3377[Abstract/Free Full Text].
|
| 13.
|
Hermonat, P. L.
1992.
Inhibition of bovine papillomavirus plasmid DNA replication by adeno-associated virus.
Virology
189:329-333[Medline].
|
| 14.
|
Hong, G.,
P. Ward, and K. I. Berns.
1992.
In vitro replication of adeno-associated virus DNA.
Proc. Natl. Acad. Sci. USA
89:4673-4677[Abstract/Free Full Text].
|
| 15.
|
Im, D.-S., and N. Muzyczka.
1990.
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity.
Cell
61:447-457[Medline].
|
| 16.
|
Kearns, W. G.,
S. A. Afione,
S. B. Fulmer,
M. C. Pang,
D. Erikson,
M. Egan,
M. J. Landrum,
T. R. Flotte, and G. R. Cutting.
1996.
Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.
Gene Ther.
3:748-755[Medline].
|
| 17.
|
Khleif, S. N.,
T. Myers,
B. J. Carter, and J. P. Trempe.
1991.
Inhibition of cellular transformation by the adeno-associated virus rep gene.
Virology
181:738-741[Medline].
|
| 18.
|
Kotin, R. M.,
J. C. Menninger,
D. C. Ward, and K. I. Berns.
1991.
Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter.
Genomics
10:831-834[Medline].
|
| 19.
|
Kyöstiö, S. R. M.,
R. S. Wonderling, and R. A. Owens.
1995.
Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 Rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein.
J. Virol.
69:6787-6796[Abstract].
|
| 20.
|
Labow, M. A., and K. I. Berns.
1988.
The adeno-associated virus rep gene inhibits replication of an adeno-associated virus/simian virus 40 hybrid genome in cos-7 cells.
J. Virol.
62:1705-1712[Abstract/Free Full Text].
|
| 21.
|
Labow, M. A.,
L. H. Graf, Jr., and K. I. Berns.
1987.
Adeno-associated virus gene expression inhibits cellular transformation by heterologous genes.
Mol. Cell. Biol.
7:1320-1325[Abstract/Free Full Text].
|
| 22.
|
Linden, R. M.,
E. Winocour, and K. I. Berns.
1996.
The recombination signals for adeno-associated virus site-specific integration.
Proc. Natl. Acad. Sci. USA
93:7966-7972[Abstract/Free Full Text].
|
| 23.
|
Maxam, A. M., and W. Gilbert.
1980.
Sequencing end-labeled DNA with base-specific cleavages.
Methods Enzymol.
65:499-560[Medline].
|
| 24.
|
Muramatsu, S. I.,
H. Mizukami,
N. S. Young, and K. E. Brown.
1996.
Nucleotide sequence and generation of an infectious clone of adeno-associated virus 3.
Virology
221:208-217[Medline].
|
| 25.
|
Ni, T.-H.,
X. Zhou,
D. M. McCarty,
I. Zolotukhin, and N. Muzyczka.
1994.
In vitro replication of adeno-associated virus DNA.
J. Virol.
68:1128-1138[Abstract/Free Full Text].
|
| 26.
|
Owens, R. A.,
J. P. Trempe,
N. Chejanovsky, and B. J. Carter.
1991.
Adeno-associated virus rep proteins produced in insect and mammalian expression systems: wild-type and dominant-negative mutant proteins bind to the viral replication origin.
Virology
184:14-22[Medline].
|
| 27.
|
Rutledge, E. A.,
C. L. Halbert, and D. W. Russell.
1998.
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.
J. Virol.
72:309-319[Abstract/Free Full Text].
|
| 28.
|
Ryan, J. H.,
S. Zolotukhin, and N. Muzyczka.
1996.
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats.
J. Virol.
70:1542-1553[Abstract].
|
| 29.
|
Samulski, R. J.,
X. Zhu,
X. Xiao,
J. D. Brook,
D. E. Housman,
N. Epstein, and L. A. Hunter.
1991.
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
EMBO J.
10:3941-3950[Medline]. (Erratum, 11:1228, 1992.)
|
| 30.
|
Smith, R. H., and R. M. Kotin.
1998.
The Rep52 gene product of adeno-associated virus is a DNA helicase with 3'-to-5' polarity.
J. Virol.
72:4874-4881[Abstract/Free Full Text].
|
| 31.
|
Smith, R. H.,
A. J. Spano, and R. M. Kotin.
1997.
The Rep78 gene product of adeno-associated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences.
J. Virol.
71:4461-4471[Abstract].
|
| 32.
|
Snyder, R. O.,
D.-S. Im,
T. Ni,
X. Xiao,
R. J. Samulski, and N. Muzyczka.
1993.
Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein.
J. Virol.
67:6096-6104[Abstract/Free Full Text].
|
| 33.
|
Snyder, R. O.,
D.-S. Im, and N. Muzyczka.
1990.
Evidence for covalent attachment of the adeno-associated virus (AAV) Rep protein to the ends of the AAV genome.
J. Virol.
64:6204-6213[Abstract/Free Full Text].
|
| 34.
|
Srivastava, A.,
E. W. Lusby, and K. I. Berns.
1983.
Nucleotide sequence and organization of the adeno-associated virus 2 genome.
J. Virol.
45:555-564[Abstract/Free Full Text].
|
| 35.
|
Urcelay, E.,
P. Ward,
S. M. Wiener,
B. Safer, and R. M. Kotin.
1995.
Asymmetric replication in vitro from a human sequence element is dependent on adeno-associated virus Rep protein.
J. Virol.
69:2038-2046[Abstract].
|
| 36.
|
Ward, P., and K. I. Berns.
1991.
In vitro rescue of an integrated hybrid adeno-associated virus/simian virus 40 genome.
J. Mol. Biol.
218:791-804[Medline].
|
| 37.
|
Weitzman, M. D.,
S. R. M. Kyöstiö,
R. M. Kotin, and R. A. Owens.
1994.
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
Proc. Natl. Acad. Sci. USA
91:5808-5812[Abstract/Free Full Text].
|
| 38.
|
Wonderling, R. S., and R. A. Owens.
1997.
Binding sites for adeno-associated virus Rep proteins within the human genome.
J. Virol.
71:2528-2534[Abstract].
|
| 39.
|
Yang, Q.,
F. Chen, and J. P. Trempe.
1994.
Characterization of cell lines that inducibility express the adeno-associated virus Rep proteins.
J. Virol.
68:4847-4856[Abstract/Free Full Text].
|
Journal of Virology, May 1999, p. 4293-4298, Vol. 73, No. 5
0022-538X/99/$04.00+0
This article has been cited by other articles:
-
Ye, C., Pintel, D. J.
(2007). Upstream AP1- and CREB-Binding Sites Confer High Basal Activity on the Adeno-Associated Virus Type 5 Capsid Gene Promoter. J. Virol.
81: 2605-2613
[Abstract]
[Full Text]
-
Ye, C., Qiu, J., Pintel, D. J.
(2006). Efficient expression of the adeno-associated virus type 5 p41 capsid gene promoter in 293 cells does not require rep.. J. Virol.
80: 6559-6567
[Abstract]
[Full Text]
-
Grimm, D., Pandey, K., Nakai, H., Storm, T. A., Kay, M. A.
(2006). Liver Transduction with Recombinant Adeno-Associated Virus Is Primarily Restricted by Capsid Serotype Not Vector Genotype. J. Virol.
80: 426-439
[Abstract]
[Full Text]
-
Jang, M. Y., Yarborough, O. H. III, Conyers, G. B., McPhie, P., Owens, R. A.
(2005). Stable Secondary Structure near the Nicking Site for Adeno-Associated Virus Type 2 Rep Proteins on Human Chromosome 19. J. Virol.
79: 3544-3556
[Abstract]
[Full Text]
-
Yan, Z., Zak, R., Zhang, Y., Engelhardt, J. F.
(2005). Inverted Terminal Repeat Sequences Are Important for Intermolecular Recombination and Circularization of Adeno-Associated Virus Genomes. J. Virol.
79: 364-379
[Abstract]
[Full Text]
-
Yoon-Robarts, M., Linden, R. M.
(2003). Identification of Active Site Residues of the Adeno-associated Virus Type 2 Rep Endonuclease. J. Biol. Chem.
278: 4912-4918
[Abstract]
[Full Text]
-
Amiss, T. J., McCarty, D. M., Skulimowski, A., Samulski, R. J.
(2003). Identification and Characterization of an Adeno-Associated Virus Integration Site in CV-1 Cells from the African Green Monkey. J. Virol.
77: 1904-1915
[Abstract]
[Full Text]
-
Qiu, J., Nayak, R., Tullis, G. E., Pintel, D. J.
(2002). Characterization of the Transcription Profile of Adeno-Associated Virus Type 5 Reveals a Number of Unique Features Compared to Previously Characterized Adeno-Associated Viruses. J. Virol.
76: 12435-12447
[Abstract]
[Full Text]
-
Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., Davidson, B. L.
(2002). Virus-Mediated Transduction of Murine Retina with Adeno-Associated Virus: Effects of Viral Capsid and Genome Size. J. Virol.
76: 7651-7660
[Abstract]
[Full Text]
-
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., Engelhardt, J. F.
(2002). Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors. J. Virol.
76: 2043-2053
[Abstract]
[Full Text]
-
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., Wilson, J. M.
(2001). Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer. J. Virol.
75: 6199-6203
[Abstract]
[Full Text]
-
Meneses, P., Berns, K. I., Winocour, E.
(2000). DNA Sequence Motifs Which Direct Adeno-Associated Virus Site-Specific Integration in a Model System. J. Virol.
74: 6213-6216
[Abstract]
[Full Text]
-
Brister, J. R., Muzyczka, N.
(1999). Rep-Mediated Nicking of the Adeno-Associated Virus Origin Requires Two Biochemical Activities, DNA Helicase Activity and Transesterification. J. Virol.
73: 9325-9336
[Abstract]
[Full Text]
-
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., Chiorini, J. A.
(2000). From the Cover: Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA
97: 3428-3432
[Abstract]
[Full Text]